Max-delbruck-centrum Fur Molekulare Medizin in Der Helmholtz-gemeinschaft

Max-delbruck-centrum Fur Molekulare Medizin (mdc) Berlin-buch

Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Geminschaft

Deutsches Rheuma-forschungszentrum Berlin

Max-delbruck-centrum Fur Molekulare Medizin Berlin-buch

Elisa Kieback

Wolfgang Uckert

Stephen Marino

Armin Rehm

Julia Bluhm

Uta Elisabeth Höpken

Thomas Blankenstein

Jehad Charo

Mario Bunse

Cynthia Perez

Simon Fillatreau

Stephen Anderton

Ulrik Stervbo

Vicky Lampropoulou

An isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. Also disclosed is a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.

Chimeric antigen receptor and CAR-T cells that bind BCMA

The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.

The present invention relates to a method for selecting a host cell population expressing a functional fusion protein comprising at least one epitope-providing amino acid sequence (epitope-tag) and the amino acid sequence of a protein that is expressed on the surface of said host cell. Preferably, the amino acid sequence comprises an alpha or beta chain of a T-cell receptor. The present invention further relates to uses of said functional T-cell receptor (TCR) alpha or beta chain fusion protein in medicine, in particular in adoptive transfer.

Epitope-tag surface expressed proteins and nucleic acids thereof

Growing community of inventors

Berlin, Germany

Elisa Kieback